Key result
Dapagliflozin reduces retinal vascular permeability and preserves adiponectin in early diabetic retinopathy.
Why the study?
The role of adiponectin in the development of diabetic microvascular complications such as diabetic retinopathy is not well understood.
Does adiponectin protect against early retinal vascular damage in a diabetic mouse model?
Does adiponectin protect against early retinal vascular damage in a diabetic mouse model?
p-value: p=<0.01
Adiponectin may play a protective role against early diabetic retinopathy by preserving retinal endothelial function, an effect that can be supported by dapagliflozin treatment.
No takes yet. Share an insight, caveat, or question.
May support adiponectin as a retinal protective target in diabetes; leaves open translation to human diabetic retinopathy.
Sakaue et al. (2022) studied Diabetic retinopathy. Dapagliflozin vs. Vehicle was evaluated on Retinal vascular permeability (extravascular Hoechst-positive area) (p=<0.01). Glucose-lowering therapy with dapagliflozin prevented the reduction of retinal adiponectin and significantly reduced retinal vascular permeability in a mouse model of early diabetic retinopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: